Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.77B 2.85B | Sales 2025 * | 23.61B 3.41B | Capitalization | 133B 19.24B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 674M | Net income 2025 * | 6.65B 960M | EV / Sales 2024 * | 5.42 x |
Net cash position 2024 * | 26.11B 3.77B | Net cash position 2025 * | 33.02B 4.77B | EV / Sales 2025 * | 4.25 x |
P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
20.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.53% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B | |
-24.53% | 8.26B |